Published in Proc Natl Acad Sci U S A on June 13, 2003
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 5.55
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
A rare-cell detector for cancer. Proc Natl Acad Sci U S A (2004) 3.95
Metastasis: recent discoveries and novel treatment strategies. Lancet (2007) 3.93
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet (2005) 2.92
Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77
Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A (2009) 2.75
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol (2011) 2.52
Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng (2009) 2.16
Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer (2014) 2.09
A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev (2008) 1.91
Mechanisms governing metastatic dormancy and reactivation. Cell (2013) 1.81
High resolution array-CGH analysis of single cells. Nucleic Acids Res (2006) 1.79
Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics (2008) 1.71
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res (2009) 1.69
FIP200, a key signaling node to coordinately regulate various cellular processes. Cell Signal (2007) 1.64
Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res (2011) 1.57
Selection and adaptation during metastatic cancer progression. Nature (2013) 1.46
Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic Leukemia. PLoS One (2015) 1.43
Metastasis: new perspectives on an old problem. Mol Cancer (2011) 1.42
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol (2004) 1.39
An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res (2010) 1.39
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35
The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle (2006) 1.34
A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis (2008) 1.34
Mechanisms of metastasis. Breast Cancer Res (2008) 1.34
Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 1.33
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res (2008) 1.24
Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One (2008) 1.22
Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis (2004) 1.22
Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics (2009) 1.21
Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle (2006) 1.21
Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells. Mol Pharm (2009) 1.20
Early dissemination seeds metastasis in breast cancer. Nature (2016) 1.20
Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia (2004) 1.20
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics (2010) 1.19
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med (2014) 1.18
Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp Cell Res (2007) 1.17
Host genetics and tumour metastasis. Br J Cancer (2004) 1.17
Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther (2006) 1.16
A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol (2010) 1.16
Life history trade-offs in cancer evolution. Nat Rev Cancer (2013) 1.16
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone. PLoS One (2012) 1.15
High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res (2008) 1.12
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res (2008) 1.09
Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature (2016) 1.08
Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol (2006) 1.08
Role of human HGFIN/nmb in breast cancer. Breast Cancer Res (2007) 1.06
Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des (2010) 1.05
Blood-brain barrier integrity and breast cancer metastasis to the brain. Patholog Res Int (2010) 1.05
MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis. Int J Mol Sci (2012) 1.04
Cell adhesion and its endocytic regulation in cell migration during neural development and cancer metastasis. Int J Mol Sci (2012) 1.04
Mismatch in mechanical and adhesive properties induces pulsating cancer cell migration in epithelial monolayer. Biophys J (2012) 1.03
Metastasis prevention by targeting the dormant niche. Nat Rev Cancer (2015) 1.03
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A (2013) 1.02
A new branch on the tree: next-generation sequencing in the study of cancer evolution. Semin Cell Dev Biol (2012) 1.00
Mitochondrial dysfunction and cancer metastasis. J Bioenerg Biomembr (2012) 1.00
Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv Exp Med Biol (2013) 1.00
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res (2012) 1.00
Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer (2004) 1.00
Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J Clin Pathol (2007) 0.99
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer (2007) 0.98
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest (2013) 0.96
Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin. Oncogene (2012) 0.96
RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer. PLoS One (2010) 0.96
From cancer genomes to cancer models: bridging the gaps. EMBO Rep (2009) 0.95
Next-generation sequencing of disseminated tumor cells. Front Oncol (2013) 0.94
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
Multicolor chromosome painting in diagnostic and research applications. Chromosome Res (2004) 0.94
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res (2015) 0.94
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. Br J Cancer (2007) 0.93
Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Am J Pathol (2005) 0.93
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat (2011) 0.93
Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression. Eur J Hum Genet (2010) 0.92
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS (2008) 0.90
Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques. J Histochem Cytochem (2008) 0.90
Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin Exp Metastasis (2007) 0.90
Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc (2012) 0.89
Cancer cell: using inflammation to invade the host. Mol Cancer (2007) 0.89
Reliable single cell array CGH for clinical samples. PLoS One (2014) 0.89
A robust method to analyze copy number alterations of less than 100 kb in single cells using oligonucleotide array CGH. PLoS One (2013) 0.88
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res (2011) 0.87
Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis (2007) 0.87
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
The hallmarks of cancer. Cell (2000) 113.05
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29
A progression puzzle. Nature (2002) 9.56
Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature (2000) 7.28
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci U S A (1994) 5.74
Connecting chromosomes, crisis, and cancer. Science (2002) 4.69
Multiple mutations and cancer. Proc Natl Acad Sci U S A (2003) 4.21
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A (1999) 3.74
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet (2002) 3.45
Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol (2002) 2.48
Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene (2001) 2.36
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol (1999) 2.22
Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst (1999) 2.21
The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol (1999) 1.71
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol (1994) 1.64
Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.63
Truncating mutations of RB1CC1 in human breast cancer. Nat Genet (2002) 1.60
Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol (2001) 1.57
Coping with complexity. multivariate analysis of tumor karyotypes. Cancer Genet Cytogenet (2002) 1.50
Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol (2001) 1.44
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res (1991) 1.25
SCOMP is superior to degenerated oligonucleotide primed-polymerase chain reaction for global amplification of minute amounts of DNA from microdissected archival tissue samples. Am J Pathol (2002) 1.24
Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer (2000) 1.11
Metastasis: the role of chance in malignancy. Nature (2002) 0.99
Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet (1996) 0.99
Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urol Res (1994) 0.94
Metastasis: objections to the same-gene model. Nature (2002) 0.92
Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes Chromosomes Cancer (1998) 0.92
Statistics in the pathology laboratory: characteristics of diagnostic tests. Pathology (2001) 0.88
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol (2006) 13.13
Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature (2010) 9.95
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol (2006) 4.35
Three-dimensional maps of all chromosomes in human male fibroblast nuclei and prometaphase rosettes. PLoS Biol (2005) 4.33
Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature (2006) 4.00
Transient colocalization of X-inactivation centres accompanies the initiation of X inactivation. Nat Cell Biol (2006) 3.66
Nuclear envelope breakdown proceeds by microtubule-induced tearing of the lamina. Cell (2002) 3.64
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet (2002) 3.45
Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol (2009) 3.36
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Global chromosome positions are transmitted through mitosis in mammalian cells. Cell (2003) 3.27
Automatic identification of subcellular phenotypes on human cell arrays. Genome Res (2004) 3.25
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A (2002) 3.05
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54
A contractile nuclear actin network drives chromosome congression in oocytes. Nature (2005) 2.45
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
Omic data from evolved E. coli are consistent with computed optimal growth from genome-scale models. Mol Syst Biol (2010) 2.41
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res (2005) 2.37
Group testing for pathway analysis improves comparability of different microarray datasets. Bioinformatics (2006) 2.37
Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics (2005) 2.36
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol (2012) 2.36
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst (2008) 2.35
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Argonaute--a database for gene regulation by mammalian microRNAs. Nucleic Acids Res (2006) 2.26
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 2.25
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst (2008) 2.20
Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle (2010) 2.18
Inheritance of gene density-related higher order chromatin arrangements in normal and tumor cell nuclei. J Cell Biol (2003) 2.12
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 2.05
Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04
Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell (2005) 2.03
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol (2005) 1.99
Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J (2003) 1.99
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A (2011) 1.90
Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol (2010) 1.85
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol (2013) 1.84
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol (2004) 1.82
Brief report: tracheal intubation using the Bonfils intubation fibrescope or direct laryngoscopy for patients with a simulated difficult airway. Can J Anaesth (2008) 1.82
KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol (2006) 1.80
CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron (2009) 1.79
GOPET: a tool for automated predictions of Gene Ontology terms. BMC Bioinformatics (2006) 1.75
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol (2012) 1.75
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle (2009) 1.75
Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet (2002) 1.70
Dynamics of HIV-1 assembly and release. PLoS Pathog (2009) 1.67
Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res (2002) 1.64
Endoscopic submucosal dissection of early cancers, flat adenomas, and submucosal tumors in the gastrointestinal tract. Clin Gastroenterol Hepatol (2008) 1.63
Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene (2005) 1.62
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One (2012) 1.61
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat Cell Biol (2002) 1.60
Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer (2010) 1.60
Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol Syst Biol (2010) 1.57
Integration of activating and inhibitory receptor signaling by regulated phosphorylation of Vav1 in immune cells. Sci Signal (2011) 1.57
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene (2004) 1.55
Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem (2007) 1.55
Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma--review of the literature preoperative differentiation of adrenal tumors. Endocr J (2008) 1.54
Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Natl Acad Sci U S A (2008) 1.53
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat (2011) 1.53
Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy. BMC Biol (2011) 1.51
A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics (2006) 1.51
Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3. BMC Genomics (2010) 1.50
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol (2012) 1.48
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene (2002) 1.48
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48